Hyppää sisältöön
    • Suomeksi
    • In English
  • Suomeksi
  • In English
  • Kirjaudu
Näytä aineisto 
  •   Etusivu
  • 3. UTUCris-artikkelit
  • Rinnakkaistallenteet
  • Näytä aineisto
  •   Etusivu
  • 3. UTUCris-artikkelit
  • Rinnakkaistallenteet
  • Näytä aineisto
JavaScript is disabled for your browser. Some features of this site may not work without it.

Clinical care advice for monitoring of islet autoantibody positive individuals with presymptomatic type 1 diabetes

Hendriks A. Emile J.; Marcovecchio M. Loredana; Besser Rachel E. J.; Bonifacio Ezio; Casteels Kristina; Elding Larsson Helena; Gemulla Gita; Lundgren Markus; Kordonouri Olga; Mallone Roberto; Pociot Flemming; Szypowska Agnieszka; Toppari Jorma; Berge Thekla von dem; Ziegler Anette G.; Mathieu Chantal; Achenbach Peter; INNODIA consortium; Fr1daStudy Group and GPPAD Study Group

Clinical care advice for monitoring of islet autoantibody positive individuals with presymptomatic type 1 diabetes

Hendriks A. Emile J.
Marcovecchio M. Loredana
Besser Rachel E. J.
Bonifacio Ezio
Casteels Kristina
Elding Larsson Helena
Gemulla Gita
Lundgren Markus
Kordonouri Olga
Mallone Roberto
Pociot Flemming
Szypowska Agnieszka
Toppari Jorma
Berge Thekla von dem
Ziegler Anette G.
Mathieu Chantal
Achenbach Peter
INNODIA consortium
Fr1daStudy Group and GPPAD Study Group
Katso/Avaa
Diabetes Metabolism Res - 2024 - Hendriks - Clinical care advice for monitoring of.pdf (942.2Kb)
Lataukset: 

John Wiley & Sons
doi:10.1002/dmrr.3777
URI
https://onlinelibrary.wiley.com/doi/full/10.1002/dmrr.3777
Näytä kaikki kuvailutiedot
Julkaisun pysyvä osoite on:
https://urn.fi/URN:NBN:fi-fe2025082787942
Tiivistelmä

Background/aim: Type 1 diabetes is an autoimmune disease that involves the development of autoantibodies against pancreatic islet beta-cell antigens, preceding clinical diagnosis by a period of preclinical disease activity. As screening activity to identify autoantibody-positive individuals increases, a rise in presymptomatic type 1 diabetes individuals seeking medical attention is expected. Current guidance on how to monitor these individuals in a safe but minimally invasive way is limited. This article aims to provide clinical guidance for monitoring individuals with presymptomatic type 1 diabetes to reduce the risk of diabetic ketoacidosis (DKA) at diagnosis.

Methods: Expert consensus was obtained from members of the Fr1da, GPPAD, and INNODIA consortia, three European diabetes research groups. The guidance covers both specialist and primary care follow-up strategies.

Results: The guidance outlines recommended monitoring approaches based on age, disease stage and clinical setting. Individuals with presymptomatic type 1 diabetes are best followed up in specialist care. For stage 1, biannual assessments of random plasma glucose and HbA1c are suggested for children, while annual assessments are recommended for adolescents and adults. For stage 2, 3-monthly clinic visits with additional home monitoring are advised. The value of repeat OGTT in stage 1 and the use of continuous glucose monitoring in stage 2 are discussed. Primary care is encouraged to monitor individuals who decline specialist care, following the guidance presented.

Conclusions: As type 1 diabetes screening programs become more prevalent, effective monitoring strategies are essential to mitigate the risk of complications such as DKA. This guidance serves as a valuable resource for clinicians, providing practical recommendations tailored to an individual's age and disease stage, both within specialist and primary care settings.

Kokoelmat
  • Rinnakkaistallenteet [27094]

Turun yliopiston kirjasto | Turun yliopisto
julkaisut@utu.fi | Tietosuoja | Saavutettavuusseloste
 

 

Tämä kokoelma

JulkaisuajatTekijätNimekkeetAsiasanatTiedekuntaLaitosOppiaineYhteisöt ja kokoelmat

Omat tiedot

Kirjaudu sisäänRekisteröidy

Turun yliopiston kirjasto | Turun yliopisto
julkaisut@utu.fi | Tietosuoja | Saavutettavuusseloste